GH Research PLC

GH Research PLC (NASDAQ: GHRS) is a biopharmaceutical company in the clinical development stage, focused on developing treatments for psychiatric and neurological conditions. Its product pipeline comprises GH001, GH002, and GH003.

Key Financial Updates:

• Robust Clinical Efficacy in Treatment-Resistant Depression (TRD): GH Research PLC has demonstrated strong clinical efficacy with its lead candidate, GH001, in the treatment of Treatment-Resistant Depression (TRD). The Phase 2b trial revealed a statistically significant reduction in depression severity, as measured by the Montgomery–Åsberg Depression Rating Scale (MADRS), with a mean reduction of -15.5 points by Day 8 compared to placebo (p<0.0001). Notably, 57.5% of patients achieved remission (MADRS ≤10) by Day 8, and this figure rose to 73.0% by Month 6 among open-label extension (OLE) completers. The treatment effect size (Cohen’s d = -2.0) suggests a large and clinically meaningful impact.
• Favorable Safety and Tolerability Profile: The safety data associated with GH001 remain favorable. No serious adverse events (SAEs) were reported in the double-blind or open-label phases. Most treatment-emergent adverse events (TEAEs), such as nausea and paresthesia, were mild to moderate and resolved within 24 hours in 93% of cases. Importantly, 99% of patients were discharge-ready within one hour of dosing, highlighting the brief psychoactive window of GH001 and its operational convenience in clinical settings.
• Operational Progress on Pivotal Program Readiness: The company is actively preparing for its pivotal program in TRD, anticipated to commence in 2026. Site selection across the US, EU, and Rest of World (RoW) regions is in progress, alongside contract research organization (CRO) engagement and regulatory consultation. Engagements with the FDA and EMA are ongoing to address outstanding investigational new drug (IND) queries. GH001 remains on partial clinical hold in the US due to rat-specific respiratory tract histology findings; however, no additional device or toxicology concerns remain, and the company is optimistic about resolving the final issue.
• Diversified Pipeline with Additional Indications and Delivery Platforms: In addition to TRD, GH Research has completed Phase 2a proof-of-concept trials for GH001 in postpartum depression (PPD) and bipolar II disorder. Its intravenous counterpart, GH002, is also advancing, with a completed Phase 1 study and pharmacokinetic equivalence established. This dual-pathway strategy – combining inhaled and intravenous formulations – positions the company to address broader psychiatric indications with flexibility in clinical application and patient targeting.
• Financial Resilience and Capital Position: As of March 31, 2025, GH Research reported a robust cash and investments position of USD 315.3 million. This strong capital base supports the company’s operational runway through its next phases of clinical development, including pivotal trials and associated regulatory milestones. No debt obligations were reported, and the company maintains full ownership of its intellectual property, with layered protections via regulatory exclusivity, patents, and complex formulation technologies.
• Competitive Positioning and Differentiation: GH001 presents substantial advantages over existing TRD therapies such as Spravato®. In head-to-head indicative comparisons, GH001 demonstrated higher remission rates (Day 2: 70% vs. 15.1%; Day 8: 57.5% vs. 10.1%) and required significantly fewer treatments (4 vs. 23 visits over 6 months). Additionally, the median duration of psychoactive effect with GH001 was only 11 minutes—much shorter than Spravato (2-3 hours) and other psychedelics (up to 6–8 hours), offering meaningful operational efficiencies in outpatient care.

Technical Observation (on the daily chart):

GHRS is in a medium-term uptrend, with price currently consolidating after a strong rally in July. While the stock has dipped slightly below the 21-day moving average (USD 15.27), it remains above the 50-day MA (USD 13.42), indicating underlying bullishness. The RSI at 48.1.5 suggests neutral momentum, and declining volume during the pullback signals limited selling pressure. Overall, the trend remains positive.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Buy’ rating has been given to GH Research PLC (NASDAQ: GHRS) at the closing market price of USD 14.50 as of July 25,2025. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is July 25,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.